B Mirror Report: Renata PLC, a listed pharmaceutical manufacturer, has started exporting medicines to Portugal for the first time as part of its strategy to expand its presence in the European market.

The company disclosed the development to the Dhaka Stock Exchange (DSE) on Thursday.

According to Renata, the first shipment includes Amantadine 100 mg capsules produced at its EU-GMP-certified Rajendrapur General Manufacturing Facility, and Fludrocortisone 0.1 mg and Cabergoline 0.5 mg tablets manufactured at its EU-GMP-certified Mirpur Potent Manufacturing Facility.

The company said entering the Portuguese market marks an important milestone in its European expansion strategy and is expected to strengthen its presence across the region.

Earlier, on July 3, Renata announced that it had received approval to export and market its Levothyroxine Sodium tablets in six European Union countries under the decentralized approval procedure. The approvals cover Ireland, Germany, Italy, Poland, Portugal, and Malta.

The thyroid medication will be manufactured at Renata’s EU-GMP-certified high-potency manufacturing facility, ensuring a safe, high-quality, and reliable supply for the new European markets.

Renata, which was listed on the stock exchange in 1979, has a paid-up capital of Tk 114.70 crore. Sponsors and directors hold 51.29% of the company’s shares, institutional investors 21.97%, foreign investors 18.85%, and the remaining 7.89% is held by general investors.